Sirnaomics Ltd., along with its subsidiary RNAimmune, Inc., a leader in mRNA-based vaccine technology, has recently achieved a milestone in their quest to develop advanced therapeutics. The U.S. Food and Drug Administration (FDA) has given the green light for RNAimmune to initiate Phase I clinical trials of RV-1770, an new mRNA vaccine designed to combat the human Respiratory Syncytial Virus (RSV). This approval marks an advancement in the field of RNAi therapeutics, particularly for RNAimmune, which specializes in mRNA vaccines and therapeutics. The trial will involve 162 healthy volunteers, split into two age cohorts, to evaluate the vaccine’s safety and effectiveness across a broad age range. This is a promising development given the substantial global health impact of RSV, which leads to significant hospitalizations annually due to respiratory conditions like pneumonia and bronchiolitis.

mRNA vaccine

The Phase I clinical trial of RV-1770 is designed to assess both the safety and tolerance of the vaccine in adults. Volunteers, ranging from 18 to 79 years old, will receive a single intramuscular dose of the vaccine in one of three dosages: 50 μg, 100 μg, or 200 μg. The study is uniquely structured to include both younger and older adults, ensuring a comprehensive understanding of the vaccine’s effects across different age groups. This approach is particularly crucial as RSV tends to severely affect both very young and elderly populations. The vaccine, a combination of mRNA technology with a proprietary lipid nanoparticle formulation, has already shown promising results in preclinical studies. It has demonstrated effective immune responses and neutralization capabilities against both type A and B strains of RSV in cotton rat studies, indicating its potential as a robust solution against RSV infections.

The development of RV-1770 is a testament to the collaborative efforts of RNAimmune and its partners. Dr. Dong Shen, President and CEO of RNAimmune, emphasized the vaccine’s potential to offer a safe and effective defense against RSV, which poses a significant threat to public health. Dr. Patrick Lu, Chairman of RNAimmune’s board, and Dr. Dewan Zeng, CEO of Zhejiang Innoforce Pharmaceuticals, the vaccine’s CDMO partner, also highlighted the vaccine’s unique mRNA sequence and nanoparticle formulation, noting its exceptional safety and efficacy in preclinical studies. This achievement underscores RNAimmune’s commitment to utilizing advanced mRNA technology to address urgent medical needs, particularly in the realm of respiratory diseases. The success of RV-1770 could pave the way for more innovative solutions in combating various infectious diseases globally.


Related News

Related Services

Plasmid CDMO Services

We provide high quality plasmids that are ideal for any phase of the drug development cycle.


AAV cGMP Manufacturing

Ranging from pilot to industrial-scale AAV packaging for both in vitro and in vivo studies.


aav icon

AAV Capsid Engineering

Proven technology paving your path to effective therapies for cancer or genetic disorder